Enzon, Inc.

Enzon Labs Inc.

Other

Genex Corporation

Aronex Pharmaceuticals, Inc.

Ma Bioservices, Inc.

Robert E Bird

Karl D Hardman

David R Filpula

Marc D Whitlow

Robert Charles Ladner

James F Wood

Michele Rollence

C Richter King

Flavia Borellini

Oleg K Glebov

Philip G Kasprzyk

Jeffrey M Ostrove

Audrey Chang-Yeh

David Jacobson-Kram

The present invention is drawn to methods and assays for the early determination of whether a test agent is a carcinogen. These novel methods and assays are used to correlate the pattern of differential gene expression from mammalian cells treated with the test agent with reference patterns of differential gene expression of mammalian cells treated with known carcinogens. Further, the present invention is drawn to methods of use of DNA and RNA isolated from the treated mammalian cells as well as kits comprising same. The present invention also is drawn to methods of determining whether a test agent is a carcinogen by measuring protein synthesis or post-translational modifications from mammalian cells treated with the test agent compared with mammalian cells treated with a known carcinogen.

Carcinogen assay

Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.

Multivalent antigen-binding proteins

Nucleic acid molecules encoding single-chain antigen-binding proteins

Methods for producing multivalent antigen-binding proteins

Improved assay for the detection of viral reverse transcriptase activity using PCR conducts the reverse transcription reaction at an acidic pH or elevated temperature. The assay is useful in testing a wide variety of biological products and tissue samples.

Methods and kits for detecting viral reverse transcriptase activity in a

The present invention relates to novel antibodies, in particular monoclonal and single chain antibodies derived therefrom which specifically bind to erbB-2, as well as diagnostic and therapeutic uses thereof. The present invention also relates to a combination of at least two erbB-2 specific antibodies which are capable of preventing and treating human malignancies wherein the malignant cells overexpress gp185.sup.erbB-2. The monoclonal antibodies of the combination preferably recognize different epitopes of the gp185 expression product of erbB-2, therefore, the antibodies do not cross react with each other. Preferably, the combination will provide for synergistic decrease in the expression of the erbB-2 gene product.

Anti-erbB-2 antibodies, combinations thereof, and therapeutic and

The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.

Immunoaffinity purification methods using single polypeptide chain

Immunoassay methods using single polypeptide chain binding molecules

Immunotheraphy using single chain polypeptide binding molecules

Single polypeptide chain binding molecules

Growing community of inventors

Rockville, MD, United States of America

Robert E Bird